Mental Health Clinics in Ashville, OH Accepting Medicare
1 Mental Health Clinics found. Showing 1 - 1
 Teays Valley Local Schools Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 385 Circleville Ave, Ashville, OH 43103 Phone: 740-983-5011 |
News Archive
New Dartmouth study offers roadmap for better risk adjustment in Medicare
The methodology Medicare uses to adjust the billions of dollars it pays health plans and hospitals to account for how sick their patients are is flawed and should be replaced, according to a new study by Dartmouth investigators published in the journal BMJ that weighed the performance of Medicare's methodology against alternatives.
WHO recommends vaccine makers move forward in mass production of H1N1 vaccine
"Saying the new H1N1 [swine flu] virus is 'unstoppable', the WHO gave drug makers a full go-ahead to manufacture vaccines against the pandemic influenza strain on Monday and said healthcare workers should be the first to get one," Reuters reports (Fox, 7/14).
Scientists evaluate growth, differentiation and function of iPSC-derived NPCs in PD
Induced pluripotent stem cells (iPSC) are a promising avenue for cell replacement therapy in neurologic diseases. For example, mouse and human iPSCs have been used to generate dopaminergic (DA) neurons that improve symptoms in rat Parkinson's disease models. Reporting in the current issue of the Journal of Parkinson's Disease, a group of scientists from Japan evaluated the growth, differentiation, and function of human-derived iPSC-derived neural progenitor cells (NPCs) in a primate model, elucidating their therapeutic potential.
Scott & White earns Joint Commission's certification for VAD Program
The Scott & White Heart & Vascular Institute in Temple has earned The Joint Commission's Gold Seal of Approval- as a hospital performing Ventricular Assist Device (VAD) as a destination therapy.
Decision Resources forecasts sales of Rituxan/MabThera, Erbitux and Herceptin
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.
› Verified 5 days ago